Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
Open Access
- 1 May 2010
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_5), v98-v102
- https://doi.org/10.1093/annonc/mdq208
Abstract
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated incidence of 1.5/100 000/year. This only covers the clinically relevant GISTs, since likely a much higher number of microscopic lesions could be found pathologically, if looked for.Keywords
This publication has 25 references indexed in Scilit:
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma GroupJournal of Clinical Oncology, 2007
- Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GISTAnnals of Surgery, 2007
- Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal TumorsAnnals of Surgery, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002